-

Leading Oncology Injectables Manufacturer Selects ValGenesis to Modernize Equipment Qualification

SANTA CLARA, Calif.--(BUSINESS WIRE)--ValGenesis Inc., the global leader in enterprise digital validation and compliance solutions, announced that a specialized Indian pharmaceutical joint venture focused on cytotoxic and oncology drug manufacturing, has selected the ValGenesis validation lifecycle management platform to modernize equipment qualification across its operations in India.

The ValGenesis platform centralizes planning, qualification protocols execution, deviation handling, approvals, and end-to-end traceability within a single system—helping organizations reduce time to production while maintaining audit-ready compliance.

Share

The company manufactures injectable and sterile products for regulated global markets, operating state-of-the-art facilities in India to support a growing portfolio and worldwide customer base.

The company selected ValGenesis for its leadership in digital validation and robust equipment qualification capabilities. The ValGenesis platform centralizes planning, qualification protocols execution, deviation handling, approvals, and end-to-end traceability within a single system—helping organizations reduce time to production while maintaining audit-ready compliance. By digitalizing these processes, the company aims to strengthen data integrity and streamline collaboration across equipment qualification and related computer system validation activities.

“Our client’s decision reflects a clear focus on modernizing validation through digital transformation,” said Wayne Baker, chief revenue officer at ValGenesis. “With the ValGenesis platform, teams gain real-time visibility, standardized execution, and full traceability — capabilities that are essential for maintaining compliance and accelerating qualification timelines in regulated manufacturing environments.”

About ValGenesis Inc.

ValGenesis, Inc. is the global leader in enterprise digital validation. Serving the life sciences industry for nearly two decades, ValGenesis enables companies to digitize their commissioning, qualification, and validation processes through its AI-enabled ValGenesis Smart GxP™ Platform, which includes solutions for risk management, cleaning validation, continued process verification, and CMC development. ValGenesis helps customers worldwide reduce costs, improve compliance, and accelerate innovation. For more information, visit valgenesis.com/.

Contacts

For further information, contact:

Althea D'Sylva | althea.dsylva@valgenesis.com

ValGenesis Inc.


Release Versions

Contacts

For further information, contact:

Althea D'Sylva | althea.dsylva@valgenesis.com

Social Media Profiles
More News From ValGenesis Inc.

ValGenesis Appoints David Horn as President 

SANTA CLARA, Calif.--(BUSINESS WIRE)--ValGenesis, the global leader in digital validation and lifecycle management solutions for the life sciences industry, today announced the appointment of David Horn as president, effective Oct. 5, 2026.Horn joins ValGenesis as the company expands its Smart GxP™ platform and VAL™ (ValGenesis AI) capabilities. As president, he will focus on strengthening the company’s financial and operating foundation, supporting global growth, and expanding relationships wit...

ValGenesis to Bring Real-World AI-Assisted Validation Insights to KENX Europe 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--ValGenesis will share real-world AI-assisted validation insights from customer pilots and production deployments at KENX Europe 2026....

Eugia Pharmaceuticals Goes Live with ValGenesis to Modernize CSV

SANTA CLARA, Calif.--(BUSINESS WIRE)--ValGenesis, Inc., the leader in enterprise digital validation, announced that Eugia Pharmaceuticals, a global specialty pharmaceutical company, has gone live with ValGenesis to modernize computer system validation (CSV) processes across its sites in India. The deployment will help enhance compliance, improve operational efficiency, and support growth. Hyderabad-based Eugia Pharma, a subsidiary of Aurobindo Pharma, develops and markets complex generics. The...
Back to Newsroom